(Q40449157)

English

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.

scientific article published on August 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. (English)

1 reference

Europe PubMed Central

20 September 2017

prostate cancer

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

20 September 2017

6

object named as

Gabor Halmos

1 reference

Europe PubMed Central

20 September 2017

Brian D Hammann

4

object named as

Brian D Hammann

1 reference

Europe PubMed Central

20 September 2017

Anton Stangelberger

1

object named as

Anton Stangelberger

1 reference

Europe PubMed Central

20 September 2017

author name string

Jozsef L Varga

3

1 reference

Europe PubMed Central

20 September 2017

Kate Groot

5

1 reference

Europe PubMed Central

20 September 2017

Ren-Zhi Cai

7

1 reference

Europe PubMed Central

20 September 2017

Marta Zarandi

8

1 reference

Europe PubMed Central

20 September 2017

publication date

1 August 2005

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

64

1 reference

Europe PubMed Central

20 September 2017

3

1 reference

Europe PubMed Central

20 September 2017

303-315

1 reference

Europe PubMed Central

20 September 2017

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone

1 reference

https://api.crossref.org/works/10.1002%2FPROS.20262

21 January 2018

Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Peptide analogs in the therapy of prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Dysregulated expression of growth factors and their receptors in the development of prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

The ErbB/HER receptor protein-tyrosine kinases and cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

The development of androgen-independent prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Hypothalamic hormones and cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

The discovery of receptor tyrosine kinases: targets for cancer therapy

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

c-erbB-2 oncoprotein: a potential biomarker of advanced prostate cancer

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1002/PROS.20262

Identifiers

10.1002/PROS.20262

1 reference

Europe PubMed Central

20 September 2017

release_otj2rtddmrcj7iffeu6hqajxam

1 reference

https://api.fatcat.wiki/v0/release/otj2rtddmrcj7iffeu6hqajxam

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40449157&oldid=2119264635"